Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (BIIB801) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion

0

Employees

0

Patents and patent applications

0

Biosimilars under development

Interview with CEO Martin Åmark, October 2023


At Xbrane Biopharma


Press Releases

02 Apr 2024

Notice of annual general meeting in Xbrane Biopharma AB

01 Apr 2024

Change of number of shares and votes in Xbrane

27 Mar 2024

XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2023

19 Mar 2024

Xbrane resolves on a directed issue of shares to guarantors in connection with the completed rights issue

14 Mar 2024

Xbrane announces the outcome of the rights issue

08 Mar 2024

Xbrane publish supplement to prospectus

04 Mar 2024

Xbrane has received additional subscription undertakings corresponding to approximately SEK 18.1 million in the Company’s rights issue

27 Feb 2024

Trading in unit rights and BTUs in Xbrane’s rights issue will commence on 29 February 2024

27 Feb 2024

Xbrane publishes prospectus in connection with the company’s partially guaranteed rights issue of approximately SEK 343 million